We are live on
!
Find out more
LP
Longview Partners Portfolio holdings
AUM
$7.06B
1-Year Est. Return
3.43%
This Fund
S&P 500
This Quarter
Est. Return
+9.38%
1 Year Est. Return
-3.43%
3 Year Est. Return
+28.48%
5 Year Est. Return
+46.59%
10 Year Est. Return
+218.87%
AUM
$14.6B
AUM Growth
+$1.1B
(+8.2%)
Cap. Flow
+$25.8M
Cap. Flow
% of AUM
0.18%
Top 10 Holdings %
Top 10 Hldgs %
48.13%
Holding
24
New
–
Increased
17
Reduced
7
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$5.05M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$4.94M |
| 3 |
Sysco
SYY
|
+$4.6M |
| 4 |
UnitedHealth
UNH
|
+$4.08M |
| 5 |
IQVIA
IQV
|
+$4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$4.94M |
| 2 |
Microsoft
MSFT
|
+$3.49M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$3.31M |
| 4 |
Booking.com
BKNG
|
+$3.17M |
| 5 |
Oracle
ORCL
|
+$2.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.84% |
| 2 | Financials | 25.69% |
| 3 | Healthcare | 24.23% |
| 4 | Consumer Discretionary | 12.58% |
| 5 | Consumer Staples | 5.59% |
Similar funds
IGAM
NAMA
RPI
MNA
CWM
SC
OCA
DE
Longview Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Longview Partners held 24 positions worth $14.6B, up 8.2% from $13.5B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Trading was light in Q3 2024: portfolio turnover was 0%. Longview Partners opened no new positions and made no exits, leaving the 24-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 28% a quarter earlier, followed by Financials and Healthcare.
- Longview Partners added most to Nike in Q3 2024, an estimated $5.05M increase.
- Longview Partners's biggest Q3 2024 reduction was Medtronic, cutting an estimated $4.94M.
- Longview Partners's ten largest holdings make up 48% of its $14.6B portfolio in Q3 2024.
- Longview Partners opened 0 new positions and closed 0 in Q3 2024.
- Longview Partners's portfolio value rose 8.2% quarter-over-quarter to $14.6B.
Based on Longview Partners's 13F filing for Q3 2024, filed 13 Nov 2024.